Send to

Choose Destination
See comment in PubMed Commons below
Clin Chim Acta. 2009 Aug;406(1-2):18-22. doi: 10.1016/j.cca.2009.04.013. Epub 2009 Apr 23.

Point-of-care fluorescence immunoassay for prostate specific antigen.

Author information

  • 1Department of Biology Education, Institute of Fusion Science, Institute of Science Education, Chonbuk National University, Jeonju, 561-756, South Korea.



Prostate specific antigen (PSA) is widely used as a clinical marker for diagnosis, screening, and prognosis of prostate cancer. A fluorescence (FL) dye-incorporated immunochromatographic assay (ICA) was developed for detection of PSA concentration in whole blood or serum.


Whole blood or serum mixed with FL-conjugated detector was loaded onto a cartridge and incubated for 12 min. The FL intensity of the cartridge was then measured in a laser FL scanner. The analytical performance of the FL-ICA system was evaluated by precision and recovery tests. The comparability of the new method was examined with an automated analyzer.


A reliable correlation between area ratio (AT/AC), reflecting FL intensity of test/control line, and PSA concentration was observed (r=0.998). The CVs of intra- and inter-assay precision in a range of 2.5-8 microg/l were <6.0% and 4.5%, respectively, and analytical recovery of the FL-ICA system fell within 6.5% at the tested samples. When the FL-ICA method was compared with Abbott AxSYM and Bayer Centaur analyzers, there were strong correlations (r=0.993 and r=0.992, p<0.0001).


The FL-ICA system with point-of-care-testing (POCT) appeared to be an easy, fast and suitable method for measurement of PSA concentration in whole blood, and needs no accessory equipment to separate serum.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center